Raul Santos: International Collaborative Insights into the Treatment of Homozygous FH
Raul Santos, Researcher at ARO Hospital Israelita Albert Einstein, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
“The therapy of Homozygous FH (HoFH) is a great challenge due to the extreme elevated LDL-C levels and the genetic variability that characterizes this disease.
Combination therapy is the rule to reduce LDL-C, and is classified in medications that depend on the LDL receptor function like statins, ezetimibe and PCSK9 inhibitors and those who are independent like Lomitapide and Evinacumab.
In this collaborative study between Canada, South Africa and Brazil led by John Mancini we showed that statins also reduce LDL-C by mechanisms other than depending on the LDL receptor alone.
HoFH is a devastating disease that needs to be diagnosed and treated ASAP.
Novel therapies are coming and hopefully will change for good how we treat this disease!”
Article: Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype.
Authors: G.B.John Mancini, Arnold Ryomoto, Isabelle Ruel, Iulia Iatan, Jacques Genest, Frederick J. Raal, Raul D. Santos, Ana Paula Marte, Brooke A. Kennedy, Liam R. Brunham, Daniel Gaudet, Miriam Larouche, Diane Brisson, Robert A. Hegele
Read the Full Article on Atherosclerosis
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs